[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200970582A1 - ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5Н-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH - Google Patents

ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5Н-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH

Info

Publication number
EA200970582A1
EA200970582A1 EA200970582A EA200970582A EA200970582A1 EA 200970582 A1 EA200970582 A1 EA 200970582A1 EA 200970582 A EA200970582 A EA 200970582A EA 200970582 A EA200970582 A EA 200970582A EA 200970582 A1 EA200970582 A1 EA 200970582A1
Authority
EA
Eurasian Patent Office
Prior art keywords
haloalkyl
6alkyl
cycloalkyl
alkyl
group
Prior art date
Application number
EA200970582A
Other languages
English (en)
Other versions
EA015559B1 (ru
Inventor
Кевин Мэттью Гардинир
Дэвид Джозеф Гармен
Эрик Джеймс Хембр
Майкл Брунавс
Хелен Джейн Секереш
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39204735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200970582(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200970582A1 publication Critical patent/EA200970582A1/ru
Publication of EA015559B1 publication Critical patent/EA015559B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Настоящее изобретение относится к соединению-антагонисту меланин-концентрирующего гормона формулы Iгде "-----" отсутствует или возможно представляет собой связь; q представляет собой 1 или 2; Rнезависимо выбран из водорода, -C-Cалкила, галогена, гидрокси, -C-Cгалогеналкила, -C-Салкокси, циано, -O-С-Сциклоалкила и -OC-Cгалогеналкила; Rвыбран из группы, состоящей из водорода, -C-Салкила, гидрокси, -C-Салкокси, циано, -C-Cгалогеналкила, -OC-Cгалогеналкила и галогена; Rвыбран из группы, состоящей из водорода, -C-Cалкила, -C-Cгалогеналкила, -С-Салкил-ОН, -С-Сциклоалкила, -СНС-Сциклоалкила, -С-Салкил-O-С-Салкила, -С(О)C-Cалкила, -С(О)C-Cгалогеналкила, -СН-тиазола, фенила, бензила, тетрагидротиопиранила и тетрагидропиранила, причем указанная циклоалкильная, тетрагидротиопиранильная, тетрагидропиранильная и тиазолильная группа может содержать в качестве заместителей одну или две группы, независимо выбранные из группы, состоящей из галогена, гидрокси, C-Cалкила и -C-Cгалогеналкила; или к его фармацевтически приемлемой соли, энантиомеру, диастереомеру или их смеси, пригодных для лечения, предотвращения или улучшения симптомов, связанных с ожирением и связанными с ним заболеваниями.
EA200970582A 2006-12-14 2007-11-15 ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5H-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH EA015559B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87001106P 2006-12-14 2006-12-14
PCT/US2007/084812 WO2008076562A1 (en) 2006-12-14 2007-11-15 5- [4- (azetidin-3-yl0xy) -phenyl] -2-phenyl-5h-thiaz0l0 [5,4-c] pyridin-4-0ne derivatives and their use as mch receptor antagonists

Publications (2)

Publication Number Publication Date
EA200970582A1 true EA200970582A1 (ru) 2010-02-26
EA015559B1 EA015559B1 (ru) 2011-08-30

Family

ID=39204735

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970582A EA015559B1 (ru) 2006-12-14 2007-11-15 ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5H-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH

Country Status (16)

Country Link
US (1) US8049013B2 (ru)
EP (1) EP2089397B1 (ru)
JP (1) JP5269804B2 (ru)
KR (1) KR20090082484A (ru)
CN (1) CN101558075A (ru)
AR (1) AR064127A1 (ru)
AU (1) AU2007334171A1 (ru)
BR (1) BRPI0721086A2 (ru)
CA (1) CA2671765A1 (ru)
CL (1) CL2007003480A1 (ru)
EA (1) EA015559B1 (ru)
ES (1) ES2392276T3 (ru)
MX (1) MX2009006319A (ru)
PE (1) PE20081572A1 (ru)
TW (1) TW200831082A (ru)
WO (1) WO2008076562A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
EP2513117B1 (en) 2009-12-18 2013-08-28 Janssen Pharmaceutica, N.V. Bicyclic thiazoles as allosteric modulators of mglur5 receptors
KR20120101551A (ko) 2009-12-18 2012-09-13 얀센 파마슈티카 엔.브이. Ｍｇｌｕｒ５ 수용체의 알로스테릭 조절자로서 바이사이클릭 티아졸
CN103209979B (zh) * 2010-07-06 2016-02-10 阿斯利康(瑞典)有限公司 治疗剂976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP6217653B2 (ja) * 2013-01-25 2017-10-25 セントラル硝子株式会社 α，α−ジフルオロアセトアルデヒドの製造方法
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
CN116082225A (zh) * 2016-08-08 2023-05-09 北京康蒂尼药业股份有限公司 一种羟尼酮的制备方法
CN116023327A (zh) * 2016-08-08 2023-04-28 北京康蒂尼药业股份有限公司 一种羟尼酮的制备方法
CN108997138A (zh) * 2018-08-17 2018-12-14 济南和润化工科技有限公司 一种无溶剂催化氢化法生产对氟苯胺的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
ES2333243T3 (es) * 2004-12-17 2010-02-18 Eli Lilly And Company Derivados de tiazolopiridinona como antagonistas del receptor de mch.

Also Published As

Publication number Publication date
MX2009006319A (es) 2009-12-14
CA2671765A1 (en) 2008-06-26
CN101558075A (zh) 2009-10-14
EP2089397B1 (en) 2012-08-29
EP2089397A1 (en) 2009-08-19
AR064127A1 (es) 2009-03-11
PE20081572A1 (es) 2008-12-27
JP2010513292A (ja) 2010-04-30
CL2007003480A1 (es) 2008-07-11
US8049013B2 (en) 2011-11-01
TW200831082A (en) 2008-08-01
BRPI0721086A2 (pt) 2014-02-25
WO2008076562A1 (en) 2008-06-26
ES2392276T3 (es) 2012-12-07
JP5269804B2 (ja) 2013-08-21
AU2007334171A1 (en) 2008-06-26
KR20090082484A (ko) 2009-07-30
EA015559B1 (ru) 2011-08-30
US20100069352A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
EA200970582A1 (ru) ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5Н-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH
WO2007125405A3 (en) Substituted 2-amino-fused heterocyclic compounds
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
CA2825172A1 (en) Indole derivative and pharmacologically acceptable salt of same
WO2006119507A3 (en) Non-nucleotide composition and method for inhibiting platelet aggregation
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
BR122019017036B8 (pt) compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
EA200870517A1 (ru) Новые антагонисты мсн-рецепторов
TNSN07014A1 (en) New heterocyclic carboxylic acid amide derivatives
NO20073208L (no) 4-fenylsubstituerte tetrahydrotsokindiner og anvendelse derav til a blokkere gjenopptak av norepinefrin, dopamin og serotonin
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
PE20080843A1 (es) Inhibidores de renina y metodo para su utilizacion
EA200300424A1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
ATE484502T1 (de) Neue verbindungen
TW200716547A (en) Piperidin-4-yl-amide derivatives
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
DE602004027409D1 (de) Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
ATE475640T1 (de) Antagonisten des opioidrezeptors
BRPI0509512A (pt) método de tratar esquizofrenia e/ou anormalidades glicorregulatórias
BRPI0518615A2 (pt) derivados de malonamida
PL2155736T3 (pl) Nowy związek, karbamoiloksyaryloalkanoiloarylopiperazyna, kompozycje farmaceutyczne zawierające ten związek oraz sposoby leczenia bólu, stanu lękowego i depresji przez podawanie tego związku
WO2009076602A8 (en) 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU